methyl 2-[(1R,3R)-3-[[(2S)-2-azido-3-methylpentanoyl]amino]-1-hydroxy-4-methylpentyl]-1,3-thiazole-4-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[(1R,3R)-3-[[(2S)-2-azido-3-methylpentanoyl]amino]-1-hydroxy-4-methylpentyl]-1,3-thiazole-4-carboxylate
• 化学式: C₁₇H₂₇N₅O₄S
• 分子量: 397.498
• InChiKey: MVXXQXZCKPUWEY-JPKGXWPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 2-[(1R,3R)-3-[[(2S)-2-azido-3-methylpentanoyl]amino]-1-hydroxy-4-methylpentyl]-1,3-thiazole-4-carboxylate 在 双(三甲基硅烷基)氨基钾 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 3.25h， 生成 methyl 2-[(1R,3R)-3-[[(2S)-2-azido-3-methylpentanoyl]-(pentoxymethyl)amino]-1-methoxy-4-methylpentyl]-1,3-thiazole-4-carboxylate
  参考文献：
  名称：

  [EN] DUAL DISULFIDE DRUG CONJUGATES
  [FR] CONJUGUÉS DE MÉDICAMENTS À DEUX GROUPES DISULFURE

  摘要：

  本发明涉及双二硫醚药物共轭物。具体而言，本发明涉及双二硫醚药物共轭物，其靶向叶酸受体，用于将共轭药物传递给哺乳动物接受者。还描述了制备和使用双二硫醚药物共轭物的方法。

  公开号：

  WO2016168471A1

文献信息

• [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
  申请人：ENDOCYTE INC

  公开号：WO2014078484A1

  公开（公告）日：2014-05-22

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说，本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病，如前列腺癌细胞，进行诊断、成像和/或治疗。
• [EN] CONJUGATES OF GARFTASE INHIBITORS<br/>[FR] CONJUGUÉS D'INHIBITEURS DE LA GARFTASE
  申请人：ENDOCYTE INC

  公开号：WO2016089879A1

  公开（公告）日：2016-06-09

  The invention described herein pertains to conjugates of GARFTase inhibitors. In particular, the invention described herein pertains to conjugates of GARFTase inhibitors that target the folate receptor for delivery of conjugated drugs to a mammalian recipient. Also described are methods of making and using conjugates of GARFTase inhibitors.

  本发明涉及GARFTase抑制剂的共轭物。具体来说，本发明涉及针对叶酸受体的GARFTase抑制剂的共轭物，用于将共轭药物传递给哺乳动物受体。还描述了制备和使用GARFTase抑制剂共轭物的方法。
• [EN] METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER AVEC UN COMPOSÉ LIGAND DE PSMA-TUBULYSINE
  申请人：ENDOCYTE INC

  公开号：WO2017205447A1

  公开（公告）日：2017-11-30

  The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

  本发明涉及用于靶向治疗的药物传递共轭物。本发明涉及使用PSMA配体-图布利西素化合物治疗表达PSMA的癌症的方法。本发明还涉及在使用PSMA配体-图布利西素化合物治疗后出现稳定疾病的患者中治疗表达PSMA的癌症的方法。
• PROCESSES FOR PREPARING TUBULYSIN DERIVATIVES AND CONJUGATES THEREOF
  申请人：ENDOCYTE, INC.

  公开号：US20140080175A1

  公开（公告）日：2014-03-20

  The invention described herein pertains to processes for preparing tubulysin derivatives, conjugates of tubulysins, and intermediates therefore.
• PROCESS FOR PREPARING TUBULYSINS
  申请人：ENDOCYTE, INC.

  公开号：US20160016993A1

  公开（公告）日：2016-01-21

  The invention described herein pertains to processes for preparing tubulysins and derivatives thereof. The invention described herein also pertains to processes for preparing tubulysin conjugates. The invention described herein also pertains to processes for preparing intermediates for preparing tubulysin conjugates. In one step, the alpha-thiazolyl alcohol is protected with triethylsilyl chloride in the presence of imidazole in an aprotic solvent.